- 1001. leukemia inhibitory factor
- [affects many systems, including hematopoietic, embryonic, bone, hepatic, neuronal, and fat tissues. ( CSP )] (UMLS (CSP) C0125606) =Amino Acid, Peptide, or Protein; Immunologic Factor ;
=Cytokine;
| - 1051. leukopoietic factor
- [ ] (UMLS (CSP) C0596833) =Organic Chemical =hematopoietic growth factor;
=Thymopoietin;
thymosin;
|
- 1002. Leukemia Inhibitory Factor (Cholinergic Differentiation Factor) Gene
- [This gene is involved in macrophage differentiation. ( NCI )] (UMLS (NCI) C1366463) LIF;
LIF Gene =Gene or Genome | - 1052. Leukoreduced
- (UMLS (HL7) C1548981) =Idea or Concept =Blood Product Processing Requirements;
|
- 1003. Leukemia Inhibitory Factor Receptor
- [Leukemia Inhibitory Factor (LIF), encoded by the LIF gene, is a polyfunctional cytokine that affects the differentiation, survival, and proliferation of a wide variety of cells in the adult and the embryo. LIF action is mediated through a high-affinity receptor complex composed of Leukemia Inhibitory Factor Receptor (a low-affinity LIF binding chain) and gp130 (a high-affinity converter subunit). The high-affinity complex also binds oncostatin M, a related cytokine. Both Leukemia Inhibitory Factor Receptor and gp130 are members of a family of cytokine receptors that includes components of the receptors for the majority of hematopoietic cytokines and for cytokines that affect other systems, including the ciliary neurotrophic factor, growth hormone and prolactin. (from OMIM) ( NCI )] (UMLS (NCI) C0125607) =Amino Acid, Peptide, or Protein; Immunologic Factor; Receptor
| - 1053. Leukoreduced Platelet Pheresis
- (UMLS (HL7) C1547255) =Intellectual Product =Blood Product Code;
|
- 1004. Leukemia Inhibitory Factor Receptor Gene
- [This gene plays a critical role in cell fate and proliferation in both embryonic and adult cells. ( NCI )] (UMLS (NCI) C1334339) LIFR;
LIFR Gene;
=Gene or Genome ;
| - 1054. Leukoregulin
- [Secreted by activated natural killer lymphocytes as a 50-kDa glycoprotein lymphokine, Leukoregulin can up regulate the expression of hyaluronan and prostaglandin-endoperoxide H synthase 2 (PTGS2), the inflammatory cyclooxygenase. Leukoregulin shows tumor growth inhibitory activity, enhances membrane permeability, and promotes the uptake of cytotoxic drugs by tumors cells without affecting these processes in normal cells. (NCI) ( NCI )] (UMLS (NCI) C0064839) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
|
- 1005. Leukemia of unspecified cell type, subacute
- (UMLS (ICD9CM) C0153924) =Neoplastic Process
| - 1055. Leukorrhea
- [A clear or white discharge from the VAGINA, consisting mainly of MUCUS. ( MSH )] (UMLS (NCI) C0023533) =Disease or Syndrome ;
=Discharge, vaginal;
|
- 1006. Leukemia Peptide Vaccine, PR1
- [A synthetic HLA-A2-restricted nonapeptide derived from proteinase 3 with potential use in cancer immunotherapy. Cytotoxic T lymphocytes (CTL) primed with proteinase 3 PR1 peptide attack leukemic cells that express proteinase 3 aberrantly. Proteinase 3 is a serine proteinase that activates progelatinase A and is involved in metastasis and angiogenesis. (NCI04) ( NCI )] (UMLS (NCI) C0879440) PR1 Leukemia Peptide Vaccine;
Proteinase 3:PR1 Peptide;
=Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 1056. Leukorrhea, not specified as infective
- (UMLS (ICD9CM) C0023534) =Disease or Syndrome ;
|
- 1007. Leukemia Plasmacytic
- [rare type of acute leukemia in which the predominating cell in the peripheral blood is the plasma cell; it is often seen in conjunction with multiple myeloma and may be a variant form of that disease. ( CSP )] (UMLS (NCI) C0023484) =Neoplastic Process =Blood (Leukemia);
Lymphoproliferative Disorder;
plasma cell neoplasm;
| - 1057. Leukostasis
- [A disorder involving the aberrant infiltration and aggregation of leukocytes into the vasculature of the body. Leukostasis is typically detected in the brain and lungs of persons with leukemia. It requires substantial ablative modalities to both reduce the number of cells present and to ensure dispersion of the aggregates. ( NCI )] (UMLS (NCI) C0282548) =Disease or Syndrome ;
=Diseases of white blood cells;
|
- 1008. Leukemia Plasmacytic (in Remission)
- [History of plasmacytic leukemia after therapy with no evidence on the peripheral blood or bone marrow of leukemia (normalization of all hematologic parameters). ( NCI )] (UMLS (NCI) C0153871) =Neoplastic Process
| - 1058. leukotaxic factor
- [ ] (UMLS (CSP) C0598143) =Biologically Active Substance ;
|
- 1009. Leukemia Stem Cell
- [A leukemia originating from a precursor bone marrow cell which is in an earlier developmental stage compared to lymphoblasts and myeloblasts. — 2003 ( NCI )] (UMLS (NCI) C1378511) Stem Cell Leukemia =Neoplastic Process
| - 1059. leukotomy
- [ ] (UMLS (CSP) C0023537) =Therapeutic or Preventive Procedure ;
|
- 1010. leukemia virus
- [not a taxonomical name; concept term for when any leukemia viruses are studied, or for when the specific virus is not mentioned; a virus causing malignant disease of the blood forming organs. ( CSP )] (UMLS (CSP) C0596828) =Virus =oncogenic virus;
| - 1060. leukotoxin
- [ ] (UMLS (CSP) C0064841) =Pharmacologic Substance; Biologically Active Substance; Hazardous or Poisonous Substance
|
- 1011. Leukemic Lymphoma
- [A usually terminal event in the clinical course of lymphomas. The term indicates the presence of atypical, clonal (malignant) lymphocytes (lymphoma cells) in the peripheral blood. —2003 ( NCI )] (UMLS (NCI) C0852709) Leukemic Phase of Lymphoma;
Leukemic Phase of Non-Hodgkin Lymphoma;
Leukemic Phase of Non-Hodgkin's Lymphoma;
=Neoplastic Process | - 1061. Leukotriene
- [family of biologically active compounds derived from arachidonic acid by oxidative metabolism through the 5-lipoxygenase pathway; participate in host defense reactions and pathophysiological conditions such as immediate hypersensitivity and inflammation; have potent actions on many essential organs and systems, including the cardiovascular, pulmonary, and central nervous system as well as the gastrointestinal tract and the immune system. ( CSP )] (UMLS (NCI) C0023545) =Eicosanoid; Biologically Active Substance =eicosanoid;
=arachidonate |
- 1012. Leukemic reticuloendotheliosis, unspecified site, extranodal and solid organ sites
- [ ] (UMLS (ICD9CM) C0375091) =Neoplastic Process
| - 1062. Leukotriene B4
- [The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990) ( MSH )] (UMLS (NCI) C0023546) =Eicosanoid; Biologically Active Substance
|
- 1013. leukemogenesis
- [The causation (or induction), development, and progression of a leukaemic disease. ( NCI )] (UMLS (CSP) C0598766) =Neoplastic Process
| - 1063. Leukotriene B4 Receptor Gene
- [This gene is in involved in G protein-coupled receptor signal transduction and chemotaxis. ( NCI )] (UMLS (NCI) C1334350) LTB4R;
LTB4R Gene =Gene or Genome ;
|
- 1014. Leukemoid reaction
- [A peripheral blood picture resembling that of leukemia or indistinguishable from it on the basis of morphologic appearance alone. (Dorland, 27th ed) ( MSH )] (UMLS (ICD9CM) C0023501) =Disease or Syndrome =leukocytosis;
MPD | - 1064. leukotriene receptor
- [Cell-surface receptors that bind LEUKOTRIENES with high affinity and trigger intracellular changes influencing the behavior of cells. The leukotriene receptor subtypes have been tentatively named according to their affinities for the endogenous leukotrienes LTB4; LTC4; LTD4; and LTE4. ( MSH )] (UMLS (CSP) C0206517) =Amino Acid, Peptide, or Protein; Receptor
|
- 1015. Leukeran
- (UMLS (NCI) C0699996) =Organic Chemical; Pharmacologic Substance; Hazardous or Poisonous Substance
| - 1065. leukovirus
- [ ] (UMLS (CSP) C0006562) =Virus
|
- 1016. Leukerin
- (UMLS (NCI) C0729099) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
| - 1066. LeuLeuOMe
- [A 2-amino acid compound with immunomodulatory activity. L-leucyl-L-leucine methyl ester (LLME) is a lysosomotropic agent entering cells via receptor-mediated endocytosis. LLME undergoes condensation process catalyzed by dipeptidyl peptidase I (DPPI) in lysosomes. Condensation of LLME leads to lysosomal rupture and DNA fragmentation in DPPI-expressing immune cells such as cytotoxic T-cells and natural killer cells. Therefore, this agent maybe able to decrease the incidence of graft versus host disease (GVHD) via cytotoxic T-cell depletion. Furthermore, LLME has the potential in augmenting antibody production when used in pretreatment of peripheral blood mononuclear cells (PBMCs), possibly via interfering gene expressions of inflammatory factors. ( NCI )] (UMLS (NCI) C0281255) =Amino Acid, Peptide, or Protein; Pharmacologic Substance
|
- 1017. leukocyte
- [white blood cell, specifically a colorless cell with a nucleus, found in blood and lymph; leukocytes are capable of amoeboid movement; they can produce antibodies and move through the walls of vessels to migrate to sites of injury, where they isolate and destroy dead tissue, foreign protein and bacteria. ( CSP )] (UMLS (CSP) C0023516) =Cell =blood cell;
allergic/immunologic body system;
Body Part;
Unclassified Ingredients =Granulocyte;
K cell;
lymphocyte;
Monocyte;
amebocyte;
LEUKOCYTES TEST;
| - 1067. LEUP/SUR
- (UMLS (NCI) C0281358) =Therapeutic or Preventive Procedure
|
- 1018. leukocyte activation disorder
- [condition in which there is a deviation from or interruption of the normal stimulation of leukocytes by specific antigens or nonspecific mitogens resulting in a lack of or limited production of cytokines. ( CSP )] (UMLS (CSP) C0596830) =Pathologic Function =Diseases of white blood cells;
| - 1068. LEUP/TMX
- (UMLS (NCI) C0281620) =Therapeutic or Preventive Procedure
|
- 1019. leukocyte activation/transformation
- [stimulation of leukocytes by specific antigens or nonspecific mitogens resulting in macromolecular synthesis and production of cytokines; followed by proliferation and differentiation of the progeny into various effector and memory cells. ( CSP )] (UMLS (CSP) C0596829) =Cell Function =Cell Mediated Immunity;
antigen presentation | - 1069. leupaxin
- [ ] (UMLS (CSP) C0674896) =Amino Acid, Peptide, or Protein
|
- 1020. Leukocyte Adhesion Deficiency
- (UMLS (NCI) C0272187) =Disease or Syndrome
| - 1070. Leupurin
- (UMLS (NCI) C0729100) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
|
- 1021. leukocyte adhesion molecule
- [receptors on leukocytes or target tissues that mediate leukocyte- target cell adhesion and, in conjunction with antigen binding to the T cell receptor, lymphocyte activation. ( CSP )] (UMLS (CSP) C0034822) =Amino Acid, Peptide, or Protein; Immunologic Factor; Receptor =Cell Surface Antigens;
Adhesion Molecule;
Receptor;
| - 1071. Leurocristine Sulfate
- [The sulfate salt of a naturally occurring vinca alkaloid. Vincristine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. (NCI04) ( NCI )] (UMLS (NCI) C0042680) =Organic Chemical; Pharmacologic Substance ;
=22-Oxovincaleukoblastine;
=VINCRISTINE SULFATE 1 MG/ML |
- 1022. leukocyte antigen 1
- [ ] (UMLS (CSP) C0598074) =Amino Acid, Peptide, or Protein; Immunologic Factor
| - 1072. Leustatin
- (UMLS (NCI) C0701346) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
|
- 1023. leukocyte antigen typing
- [test to detect genetic markers on white blood cells. ( CSP )] (UMLS (CSP) C0596831) =Laboratory Procedure =histocompatibility typing;
| - 1073. leuvectin
- [An agent that delivers the gene for interleukin-2 (IL-2) into cells to increase production of IL-2 by the cells. ( NCI )] (UMLS (NCI) C0677671) =Organic Chemical; Pharmacologic Substance ;
|
- 1024. leukocyte count
- [number of white blood cells per unit volume in venous blood. ( CSP )] (UMLS (CSP) C0023508) =Laboratory Procedure =blood cell count;
| - 1074. LEV/TMX
- (UMLS (NCI) C0281023) =Therapeutic or Preventive Procedure
|
- 1025. leukocyte depletion therapy
- [immunosuppression by reduction of leukocytes. ( CSP )] (UMLS (CSP) C0596832) =Therapeutic or Preventive Procedure =blood cell depletion therapy;
| - 1075. LEVALLORPHAN
- [An opioid antagonist with properties similar to those of NALOXONE; in addition it also possesses some agonist properties. It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants. (From Martindale, The Extra Pharmacopoeia, 30th ed, p683) ( MSH )] (UMLS (NCI) C0023554) =Organic Chemical; Pharmacologic Substance
|
- 1026. leukocyte elastase
- [An enzyme that catalyzes the hydrolysis of proteins, including elastin. It cleaves preferentially bonds at the carboxyl side of Ala and Val, with greater specificity for Ala. EC 3.4.21.37. ( MSH )] (UMLS (CSP) C0064833) =Amino Acid, Peptide, or Protein; Enzyme ;
| - 1076. Levallorphan Tartrate
- (UMLS (NCI) C0770439) =Organic Chemical; Pharmacologic Substance
|
- 1027. leukocyte homing
- [ ] (UMLS (CSP) C1328922) =Cell Function; ;
| - 1077. Levator Ani
- (UMLS (NCI) C0224384) =Body Part, Organ, or Organ Component
|
- 1028. leukocyte mediator
- [ ] (UMLS (CSP) C1328923) =Amino Acid, Peptide, or Protein; Immunologic Factor ;
| - 1078. LEVATOR MUSC SUSPENSION
- (UMLS (ICD9CM) C0194512) =Therapeutic or Preventive Procedure
|
- 1029. leukocyte oxidative burst
- [large increase in oxygen uptake by neutrophils and most types of tissue macrophages through activation of an NADPH/cytochrome b-dependent oxidase that reduces oxygen to a superoxide. ( CSP )] (UMLS (CSP) C0085416) =Cell Function ;
=bactericidal immunity;
| - 1079. Levator Palpebrae Superioris
- (UMLS (NCI) C0224134) =Body Part, Organ, or Organ Component
|
- 1030. leukocyte preservation
- [ ] (UMLS (CSP) C0598022) =Laboratory Procedure ;
| - 1080. Level 1 skin repair.
- (UMLS (HL7) C1547505) =Intellectual Product =Ambulatory Payment Classification Code;
|
- 1031. leukocyte proliferation
- [ ] (UMLS (CSP) C0598773) =Cell Function
| - 1081. Level of Care
- (UMLS (HL7) C1547668) =Idea or Concept =HL7 Vocabulary Version 2.5;
=Intensive care;
Critical care;
Routine;
Surgery;
Ambulatory;
Emergency;
Isolation;
|
- 1032. Leukocyte Therapy
- (UMLS (NCI) C0281179) =Therapeutic or Preventive Procedure
| - 1082. Level of care
- (UMLS (HL7) C1548572) =Intellectual Product =Location characteristic ID;
|
- 1033. Leukocyte Trafficking
- [The circulation of white blood cells from the blood stream to tissues or secondary lymphoid organs, to the lymphatics, and back to the bloodstream via the thoracic duct. ( NCI )] (UMLS (NCI) C1326500) =Cell Function
| - 1083. Level of Evidence
- [A formal ranking system of the strength of evidence linked to a reported result. ( NCI )] (UMLS (NCI) C0393009) =Finding
|
- 1034. leukocyte transformation
- [ ] (UMLS (CSP) C0920709) =Cell Function ;
| - 1084. Levelock Village
- (UMLS (HL7) C1550910) =Population Group =NativeEntityAlaska;
|
- 1035. leukocyte transfusion
- [transfer of leukocytes from a donor to a recipient or reinfusion to the donor. ( CSP )] (UMLS (CSP) C0086548) =Therapeutic or Preventive Procedure ;
=blood transfusion;
| - 1085. Leviviridae
- [A family of bacteriophages that infects enterobacteria, CAULOBACTER, and PSEUDOMONAS. The genome consists of linear, positive-sense single-stranded RNA. ( MSH )] (UMLS (CSP) C0206388) =Virus
|
- 1036. Leukocyte Tyrosine Kinase Gene
- [This gene plays a role in leukocyte tyrosine kinase signal transduction and diverse cellular regulatory pathways. ( NCI )] (UMLS (NCI) C1334352) LTK;
LTK Gene =Gene or Genome ;
| - 1086. Levo-Dromoran
- (UMLS (NCI) C1450007) =Organic Chemical; Pharmacologic Substance
|
- 1037. Leukocytes
- (UMLS (HL7) C1547962) =Intellectual Product =Specimen Source Codes;
| - 1087. LEVOBETAXOLOL
- [The S-isomer of betaxolol, a selective beta-1 adrenergic receptor antagonist with anti-glaucoma activity and devoid of intrinsic sympathomimetic activity. When applied topically in the eye, levobetaxolol reduces aqueous humor secretion and lowers the intraocular pressure (IOP). ( NCI )] (UMLS (NCI) C1171274) =Organic Chemical; Pharmacologic Substance ;
|
- 1038. Leukocytes
- (UMLS (HL7) C1550647) =Body Substance =SpecimenEntityType;
| - 1088. LEVOBETAXOLOL HYDROCHLORIDE
- [The hydrochloride salt form of levobetaxolol, the S-isomer of the -selective beta-1 adrenergic receptor antagonist betaxolol with anti-glaucoma activity and devoid of intrinsic sympathomimetic activity. When applied topically in the eye, levobetaxolol reduces aqueous humor secretion and lowers the intraocular pressure (IOP). ( NCI )] (UMLS (NCI) C0876234) =Organic Chemical; Pharmacologic Substance ;
|
- 1039. Leukocytic Cast Formation
- (UMLS (NCI) C1334393) =Finding; ;
| - 1089. LEVOBUNOLOL
- [A naphthalenone and non-cardioselective adrenergic beta-receptor antagonist with anti-glaucoma activity. Upon administration in the eye, levobunolol blocks beta-adrenergic receptors, thereby causing vasoconstriction. Levobunolol also decreases ciliary's body production of aqueous humor, leading to a decrease in aqueous humor. ( NCI )] (UMLS (NCI) C0006388) =Organic Chemical; Pharmacologic Substance =Propanolamines;
[OP101] BETA-BLOCKERS, TOPICAL OPHTHALMIC =LEVOBUNOLOL HYDROCHLORIDE;
|
- 1040. LEUKOCYTOPENIA NOS
- [reduction in the number of leukocytes in the blood, the count being 5000 per cubic millimeter or less. ( CSP )] (UMLS (ICD9CM) C0023530) =Disease or Syndrome ;
=Diseases of white blood cells;
=agranulocytosis;
LYMPHOCYTOPENIA;
agranulocytosis;
LYMPHOCYTOPENIA;
| - 1090. LEVOCABASTINE
- [A synthetic piperidine derivative with antihistamine properties. Levocabastine is a second generation histamine-1 receptor antagonist. When applied locally into the eye as a topical solution, this agent reduces itching, rhinorrhea and symptoms of allergic rhinitis or conjunctivitis. ( NCI )] (UMLS (NCI) C0064870) =Organic Chemical; Pharmacologic Substance ;
=Piperidines;
[OP900] OPHTHALMICS, OTHER =4-Piperidinecarboxylic Acid, 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, Monohydrochloride,(-)-(1(cis)3alpha,4beta)-;
|
- 1041. leukocytosis
- [transient increase in the number of leukocytes in a body fluid. ( CSP )] (UMLS (CSP) C0023518) =Pathologic Function ;
=Diseases of white blood cells;
Pathologic Process =lymphocytosis;
Leukemoid reaction;
lymphocytosis | - 1091. LEVOCETIRIZINE
- (UMLS (NCI) C1174893) =Organic Chemical; Pharmacologic Substance ;
|
- 1042. LEUKODYSTROPHY
- [group of diseases affecting the white matter of the brain, especially the cerebral hemispheres, due to defects in the formation and maintenance of myelin in infants and children. ( CSP )] (UMLS (ICD9CM) C0023520) =Disease or Syndrome ;
=CEREB DEGENERATION NOS;
=beta galactocerebrosidase deficiency;
arylsulfatase A deficiency;
adrenoleukodystrophy | - 1092. levofloxacin
- [A substance used to treat bacterial infections. It belongs to the family of drugs called quinolone antibiotics. ( NCI )] (UMLS (NCI) C0282386) =Organic Chemical; Antibiotic ;
=ofloxacin;
[AM900] ANTI-INFECTIVES, OTHER;
[OP201] ANTIBACTERIALS, TOPICAL OPHTHALMIC;
=LEVOFLOXACIN 25 MG/ML;
LEVOFLOXACIN 250 MG;
LEVOFLOXACIN 5 MG/ML;
LEVOFLOXACIN 500 MG;
LEVOFLOXACIN 750 MG;
LEVOFLOXACIN 0.5 % |
- 1043. Leukoencephalopathy
- [White matter changes first described in children with leukemia, associated with radiation and chemotherapy injury, often associated with methotrexate; pathologically characterised by diffuse reactive astrocytosis with multiple areas of necrotic foci without inflammation. ( NCI )] (UMLS (NCI) C0270612) =Disease or Syndrome
| - 1093. Levomenthol
- [A levo isomer of menthol, an organic compound made synthetically or obtained from peppermint or mint oils with flavoring and local anesthetic properties. When added to pharmaceuticals and foods, menthol functions as a fortifier for peppermint flavors. It also has a counterirritant effect on skin and mucous membranes, thereby, producing a local analgesic or anesthetic effect. ( NCI )] (UMLS (NCI) C0771655) =Organic Chemical; Pharmacologic Substance
|
- 1044. Leukokeratosis of Oral Mucosa
- [white patch seen on the oral mucosa; considered a premalignant condition and is often tobacco-induced. ( CSP )] (UMLS (NCI) C0023532) =Neoplastic Process ;
=Keratotic Plaque;
Lip and Oral Cavity Neoplasm;
oral pharyngeal hyperplasia;
=Hairy Leukoplakia of Mouth | - 1094. Levomepromazine Maleate
- (UMLS (NCI) C0607673) =Organic Chemical; Pharmacologic Substance
|
- 1045. Leukoplakia of Buccal Mucosa
- (UMLS (NCI) C0399470) =Neoplastic Process
| - 1095. Levonantradol
- [A synthetic cannabinoid analogue of delta (9)-tetrahydrocannabinol (delta(9)-THC) with antiemetic and anti-analgesic properties. Although its precise mechanism of action is unknown, levonantradol appears to bind and activate the cannabinoid receptors CB1 and/or CB2. (NCI04) ( NCI )] (UMLS (NCI) C0125660) =Organic Chemical; Pharmacologic Substance ;
|
- 1046. Leukoplakia of Lips
- (UMLS (NCI) C0399602) =Neoplastic Process
| - 1096. levopa
- [ ] (UMLS (CSP) C0700880) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Neuroreactive Substance or Biogenic Amine
|
- 1047. Leukoplakia of oral mucosa, including tongue
- [ ] (UMLS (ICD9CM) C1112530) LEUKOPLAKIA ORAL MUCOSA =Disease or Syndrome ;
| - 1097. LEVORPHANOL
- [A synthetic derivative of morphine with analgesic activities. Levorphanol mimics the actions of morphine, however, it is about 8 times more potent than morphine. This agent binds to opioid mu receptors, thereby producing analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence. ( NCI )] (UMLS (NCI) C0023586) =Organic Chemical; Pharmacologic Substance =[CN101] OPIOID ANALGESICS;
morphinan =dextromethorphan;
2H-10,4a-Iminoethanophenanthren-6-ol, 1,3,4,9,10,10a-hexahydro-11-methyl-, Tartrate;
|
- 1048. Leukoplakia of the Vagina
- (UMLS (NCI) C0156385) =Neoplastic Process
| - 1098. LEVOXADROL
- (UMLS (NCI) C0125663) =Organic Chemical; Pharmacologic Substance ;
|
- 1049. Leukoplakia of Tongue
- (UMLS (NCI) C0241435) =Neoplastic Process
| - 1099. Lewis Y Antigen
- [A carbohydrate molecule expressed on the surface of solid tumors including lung, intestinal, breast, prostate, pancreatic, esophageal, stomach, colon, rectal or ovarian cancers. ( NCI )] (UMLS (NCI) C0298751) =Carbohydrate; Immunologic Factor
|
- 1050. leukopoiesis
- [forming and production of leukocytes. ( CSP )] (UMLS (CSP) C0525007) =Organ or Tissue Function ;
=hematopoiesis;
| - 1100. Lewy body
- [filamentous cytoplasmic inclusions of unknown pathogenesis in some brain areas; found in association with several disabling and dementing neurodegenerative disorders. ( CSP )] (UMLS (CSP) C0085200) =Cell Component ;
=cellular inclusions;
|
home
